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Abstract: Frizzled7 is arguably the most studied member of the Frizzled family, which are the cognate
Wnt receptors. Frizzled7 is highly conserved through evolution, from Hydra through to humans,
and is expressed in diverse organisms, tissues and human disease contexts. Frizzled receptors can
homo- or hetero-polymerise and associate with several co-receptors to transmit Wnt signalling.
Notably, Frizzled7 can transmit signalling via multiple Wnt transduction pathways and bind to
several different Wnt ligands, Frizzled receptors and co-receptors. These promiscuous binding
and functional properties are thought to underlie the pivotal role Frizzled7 plays in embryonic
developmental and stem cell function. Recent studies have identified that Frizzled7 is upregulated
in diverse human cancers, and promotes proliferation, progression and invasion, and orchestrates
cellular transitions that underscore cancer metastasis. Importantly, Frizzled7 is able to regulate Wnt
signalling activity even in cancer cells which have mutations to down-stream signal transducers.
In this review we discuss the various aspects of Frizzled7 signalling and function, and the implications
these have for therapeutic targeting of Frizzled7 in cancer.
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1. Introduction
Frizzled7 (FZD7) is located on human chromosome 2q33 and contains 3859 nucleotides that
produce a 574 amino acid transmembrane protein, which belongs to a family of Wnt receptors. The Wnt
signalling pathway regulates a diverse repertoire of cellular functions, playing critical roles during
embryonic development, stem cell function and is often deregulated in cancer. Frizzled (Fzd) receptors
have an extracellular N-terminal with a conserved cysteine rich domain (CRD), which is responsible for
binding to Wnt ligands, seven transmembrane domains and an intracellular C-terminal with a putative
PDZ binding domain. The number of Fzd genes varies between class of organism; mammals have ten
Fzd’s, Drosophila have four, whilst C. elegans have three. Sequence analysis indicates that vertebrate Fzd
genes can be divided into discrete classes based on structural homology. Fzd1, Fzd2 and Fzd7 share
approximately 97% identity, Fzd5 and Fzd8 share 70% identity, Fzd4, Fzd9 and Fzd10 share 65% identity
and Fzd3 and Fzd6 share 50% amino acid identity [1,2]. Fzd receptors are able to associate with several
distinct co-receptors giving the Wnt pathway considerable complexity and flexibility. The cytoplasmic
components of Wnt signalling are frequently mutated in cancer, for example ~90% of colorectal cancers
contain mutations which activate the Wnt pathway [3]. However, it is becoming clear that the Wnt receptor
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complex also plays an important role during cancer despite mutations in the downstream components of
the pathway. There is now convincing data to demonstrate that the level at which the Wnt pathway is
activated is instrumental to phenotypic outcomes, and that the strength of the signal is regulated at multiple
points in the signalling cascade including the Wnt/Fzd receptor complex. Fzd7 is of particular interest
as it is the Wnt receptor most commonly up-regulated in several different cancers and can also transmit
signals through the different arms of the Wnt pathway referred to broadly as canonical (Wnt/β-catenin
dependent) and non-canonical (Wnt/β-catenin independent). The decision of which pathway Fzd7 will
signal through upon ligand binding is still a subject of current research in the field, but appears to be
dependent on the availability of co-receptors, Wnts and the cellular and extra-cellular milieu. As both the
canonical and non-canonical pathways are deregulated in many different cancers, Fzd7 offers an exciting
target for therapeutic intervention and will be the main focus of this review.
2. Wnt Signalling
The Wnt1 gene (originally called Int1) was first identified during a screen to identify oncogenes
capable of inducing breast tumours in mice when mutated by infection with mouse mammary tumour
virus (MMTV) [4]. Since then, a whole family of Wnt proteins has been discovered (19 in mammals,
including humans) which are highly conserved from humans through to the simplest free living
organisms, placozoans [5] and sponges [6]. Experiments in Drosophila and Xenopus demonstrate that
Wnt1 is an important regulator of many cell functions during development including proliferation,
migration, differentiation, apoptosis and cell polarity. These experiments, and subsequent ones,
identified that Wnt1 is a homolog of Drosophila Wingless (Wg) and is the ligand for a signalling pathway
which signals through Glycogen synthase kinase-3 beta (GSK3β), β-catenin and the transcription
factors T-cell factor-4 (Tcf4)/Lymphoid enhancer binding factor-1 (Lef1), and was consequently
called the Wnt pathway (an amalgam of “Wg” and “Int1”) [7]. In addition to its critical role during
development, the Wnt pathway also controls the activity of stem cells in adult tissues including the
intestine, stomach, liver, ovary, breast and hair follicle, during homeostasis and regeneration [8].
Wnt proteins are ~40 KDa in size and mediate relatively close-range signalling between cells.
Recent evidence for the mechanism of this short-range signalling suggests that lipid modifications to
Wnt by the palmitoyltransferase enzyme Porcupine in the endoplasmic reticulum target it for tethering
to the membrane by the carrier protein Wntless [9]. Thus exocytosed Wnt proteins are thought to
be either attached to the cell membrane or expelled in secretory vesicles, with very recent evidence
suggesting that cell division, and not diffusion, is the primary mechanism for forming Wnt gradients,
at least in the mammalian intestinal crypt [10]. However, studies in Drosophila suggest Wg can act
as both a short and long-range inducer, which presents an interesting paradox; how do Wg ligands,
which are hydrophobic and prone to form aggregates in an aqueous extracellular environment, act
as long-range inducers if their lipid moieties confer high affinity for membrane tethering? Recent
research from Roel Nusse’s lab has addressed this long standing question. Secreted Wg-interacting
molecule (Swim), a member of the Lipocalin family of transporter proteins, can bind with nanomolar
affinity to Wg, chaperoning Wg through the extracellular milieu, whilst preserving Wg solubility
and signalling activity [11]. As such, RNAi-mediated Swim knockdown disrupts the identity of cells
positioned distally from the local Wg source, demonstrating that they require long-range Wg signaling.
As anticipated, Swim reduction resembles Wg mutant long-range phenotypes [11]. Furthermore,
seminal work from Vivian Budnik’s group has elegantly demonstrated in the Drosophila neuromuscular
junction (NMJ) that Wg signal transmission can occur via exosome release, which contain the Wnt
binding protein Evenness Interrupted (Evi) [12]. Evi is required for Wg secretion on the pre-synaptic
side, as Evi mutants phenocopy Wg mutant tissues [13]. Additionally, Evi plays an important cell
autonomous role targeting dGRIP, a Wg-receptor-interacting protein, to post-synaptic sites where it
facilitates post-synaptic Wg signal transmission [13]. Besides its role in transporting Wg via exosomes
across the NMJ, Evi also functions in the retromer system, where it is recycled from endosome to the
Golgi apparatus for subsequent rounds of Wg release at the plasma membrane [12].
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3. Canonical and Non-Canonical Signalling
Wnt signalling is broadly divided into canonical and non-canonical pathways based primarily
on whether signalling activates β-catenin (for canonical), and associated phenotypes including
transformation of mammary epithelial cells and Xenopus axis duplication for canonical signalling
and orientation of hairs on the wing surface of Drosophila for non-canonical. The interaction between
the Wnt ligand and the receptors it associates with on neighbouring cells determines which of these
pathways is activated (Figure 1). Some Wnts that have been shown over many years of research to
robustly activate particular pathways, such as Wnt3a and Wnt2b activating canonical signalling whilst
Wnt5a and Wnt11 predominantly activate non-canonical pathways, however, this is by no means an
exclusive activation of just one pathway. Indeed, several studies now indicate considerable cross-talk
between the canonical and non-canonical pathways and thus this division should not been considered
entirely separate but rather as a signalling network depending on cell and situation context [14].
Consequently, Wnt5a provides an excellent example of how a single Wnt ligand can activate discrete
signalling outcomes, depending on cellular context and receptor availability. Well studied for its
role in PCP and Wnt/Ca2+ activation (discussed in detail below), Wnt5a in co-operation with Ror2
can inhibit Wnt3a-mediated canonical Wnt signalling through promoting β-catenin degradation
independent of Gsk-3 [15,16]. Demonstrated in parallel, Wnt5a/Ca2+ signalling triggers calcium
calmodulin dependent protein kinase II (CaMKII) activation, which induces the Transforming growth
factor-beta-activated kinase 1 (TAK1)-Nemo-like kinase (NLK)-Mitogen-activated-protein-kinase (MAPK)
pathway, shown to phosphorylate TCF/LEF factors and inhibit the interaction of the β-catenin/TCF
complex with DNA. Thus, the TAK1-NLK-MAPK-like pathway, via Wnt5a/Ca2+ signaling, negatively
regulates the Wnt/β-catenin signalling pathway [17,18]. Interestingly, in other contexts, Wnt5a can activate
β-catenin/TCF/LEF-mediated transcription in the presence of the appropriate Fzd receptor, Fzd4 [15].
The pivotal effector of the canonical Wnt pathway is the co-transcription factor β-catenin. In the
absence of active Wnt signalling, β-catenin is primarily localised to cell-cell adherens junctions and
any free cytoplasmic β-catenin is rapidly phosphorylated by GSK3 in a degradation complex which
targets β-catenin for proteosomal degradation. The destruction complex also includes Adenamatous
polyposis coli (Apc), Casein kinase 1 (CK1) and Axin to facilitate phosphorylation of β-catenin.
During canonical Wnt signaling, Wnt ligands bind to transmembrane Fzd receptors and low-density
lipoprotein receptor-related protein 5 or 6 (Lrp5/6) co-receptors. Once activated, this receptor complex
associates with the cytosolic scaffold protein Dishevelled (Dvl) to inhibit GSK3 enzyme activity.
Consequently, β-catenin escapes phosphorylation and subsequent degradation, accumulates in the
cytoplasm and translocates into the nucleus. β-catenin cannot bind to DNA directly but instead
regulates transcription by associating with the transcription factor complex Tcf4/Lef1 that bind to
conserved E-box sequences in regulatory elements of genes. Wnt1 and Wnt3a are prototypical examples
of ligands that consistently activate this pathway [19].
The non-canonical Wnt pathway is defined as being able to signal independent of β-catenin and
has two arms; the Planar Cell Polarity (PCP) pathway and the Calcium pathway (Ca2+). PCP signalling
is activated when Wnt ligands including Wnt5a [20], Wnt7a [21], Wnt8b [22] or Wnt11 [23,24] bind
to Fzd receptors and associated receptor tyrosine kinases such as Ror2 or Ryk [25], thus allowing for
significant complexity in the transmission of the signal. Depending on which Wnt/receptor complex
is activated, a variety of cytoplasmic PCP pathway signal transduction components are then activated
including DVL, Cdc42, c-JUN N-terminal Kinase (Jnk) and the GTPases RhoA, Rac1 [26]. The PCP
pathway also includes the so called “core” components (Fzd, Dsh, Celsr, Vangl and Prickle) which
set up cell polarity within the plane of the epithelial sheet [27]. Although primarily involved in cell
polarity and migration, recent data suggests that PCP signalling can also promote proliferation in
several different cancers [28–32].
The Wnt/Ca2+ pathway derives originally from the observations that over-expression of Wnt5a
or rat Fzd2 can cause an increase in intracellular calcium in zebrafish [33] and can activate protein
kinase C (PKC) and calcium/calmodulin-dependent protein kinase (CaM kinase) in Xenopus [34].
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Wnt/Fzd ligand receptor interaction with participating co-receptor Ror 1/2 leads to the production of
inositol 1,4,5-triphosphate (IP3) and 1,2 diacylglycerol (DAG) and calcium from membrane-bound
phospholipid phosphatidyl inositol 4,5-bisphosphate via the action of membrane-bound enzyme
phospholipase C (PLC). PLC then modifies IP3 and DAG allowing IP3 to diffuse through the cytosol
and interact with calcium channels present on the endoplasmic reticulum, which result in the release
of calcium ions. Calcium in conjunction with calmodulin activates CaMKII. Meanwhile, DAG and
intracellular calcium activate PKC. PKC and CaMKII can activate various regulatory proteins, including
NFκB and CREB, which are nuclear transcription factors, and thus regulate target gene expression [35].
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RSPO it is RNF43/ZNRF3 which is internalised and degraded and thus Fzd7/Lrp5/6 remains on the 
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with Ror2 or Ryk to transmit non‐canonical Wnt signals from ligands including Wnt5 or Wnt 11, either 
via PCP or Ca2+; (D) Fzd7 can associate with G Protein α (GP α) to transmit signals from Wnt8 via the 
PCP pathway; (E) Fzd7 can associate with Syndican4 (Sdc4) and R‐Spo to transmit Wnt5a signals via 
internalisation of the whole receptor complex and ligand which then activates PCP signaling. 
Figure 1. Fzd7 receptor complexes and signalling output. (A) Fzd7 (Fz7) can associate with Lrp5/6 to
transmit canonical Wnt signaling from ligands including Wnt3. However RNF43/ZNRF3 ubiquitylates
Fzd7 and targets it for internalisation and protesomal degradation, thus resulting in turn-over of the
receptor complex and low canonical Wnt signaling; (B) In the presence of Lgr4/5, and RSPO it is
RNF43/ZNRF3 which is internalised and degraded and thus Fzd7/Lrp5/6 remains on the cell surface
to transmit Wnt signalling and canonical signalling output is high; (C) Fzd7 can associate with Ror2
or Ryk to transmit non-canonical Wnt signals from ligands including Wnt5 or Wnt 11, either via
PCP or Ca2+; (D) Fzd7 can associate with G Protein α (GP α) to transmit signals from Wnt8 via the
PCP pathway; (E) Fzd7 can associate with Syndican4 (Sdc4) and R-Spo to transmit Wnt5a signals via
internalisation of the whole receptor complex and ligand which then activates PCP signaling.
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4. Regulators of Wnt/Fzd Receptor Interaction
In canonical Wnt signalling, Fzd receptors respond to Wnt proteins in the presence of co-receptor
LRP5/6 to activate and propagate the canonical Wnt/β-catenin pathway. Alternatively, Fzd receptors
can respond to Wnt proteins in the presence of the Wnt co-receptor Ror2 to activate the non-canonical
pathway [20]. Thus, it seems likely that the decision for a cell to activate canonical or non-canonical Wnt
signalling largely depends on the receptor/co-receptor/ligand combination and availability of these
components, which is a current research focus in the field (Table 1 and Figure 1) [14]. This interaction
between Wnt ligand and its co-receptors is also regulated by several other proteins, to ensure that Wnt
signalling is tightly regulated as described below.
4.1. sFRP Protein Family
The family of secreted frizzled-related proteins (sFRPs) is comprised of five secreted glycoproteins
(sFRP-1, sFRP-2, sFRP-3, sFRP-4, and sFRP-5), which bind directly to Wnts, thereby altering their
ability to bind to the Wnt receptor complex [36]. All sFRP family members contain an N-terminal
domain that is 30%–50% homologous to the CRD of Frizzled receptors, which is considered both
necessary and sufficient for Wnt binding and inhibition [37,38]. In contrast to Fzd family proteins,
sFRPs lack a transmembrane region and the cytoplasmic domain required for signal transduction into
the cells. However, other structure and function analyses of sFRP1 demonstrate that both the CRD and
C-terminal Netrin-related motif (NTR) domains are required for optimal Wnt inhibition [39].
The crystal structures of the CRDs from mouse Fzd8 and sFRP3 reveal the potential to form
dimers [40], which is supported by evidence showing Fzd and sFRP proteins can form homo- and
heteromeric complexes via the CRD [41]. These findings may imply that sFRPs have multiple modes in
which they can inhibit Wnt signalling. Unlike Dkks, which specifically target and inhibit canonical Wnt
signalling, sFRPs can bind directly to Wnt ligands, thereby inhibiting both canonical and non-canonical
Wnt signalling [36,42].
It should be noted that sFRPs do not always inhibit Wnt signalling, as nanomolar concentrations
of sFRP1 increase Wnt3a signalling in HEK293 cells, whilst higher concentrations inhibit Wnt
signalling [43]. In addition to the concentration specific activities of sFRPs [44], cell type and the
expression of Fzd receptors [43] and GSK3 [45] have also been show to modulate the ability of SFRPs to
inhibit Wnt signalling. For example, sFRP2 has been shown to inhibit Wnt3a signalling in ES cells [44],
whilst in HEK293 cells it inhibits Wnt signalling [46].
4.2. Wnt Inhibitory Factor 1 (WIF-1)
Similar to SFRPs, Wnt inhibitory factor 1 (WIF-1) is also able to bind to Wnt ligands and inhibit
Wnt signalling [47]. WIF-1 is conserved amongst the vertebrates and consists of an N-terminal secretion
signal sequence, the WIF domain, five Epidermal growth factor (EGF)-like domains and a hydrophilic
C terminus [48]. Structural analysis, site mutagenesis and cell assays show that Wnt can bind to the
WIF domain and the EGF-like domains of WIF-1 [48].
WIF-1 inhibits Wnt signalling during development to help regulate Wnt expression in the paraxial
mesoderm [47], and its promoter region is frequently methylated, and consequently downregulated in
many cancers as detailed below.
4.3. Dkk Protein Family
There are four Dickkopf (Dkk) proteins in the vertebrate genome, Dkk-1, -2, -3 and -4. Dkk
proteins selectively antagonise canonical Wnt signalling by binding to Lrp5/6, thus preventing Fzd
and Wnt to form a ternary complex [49]. They can also modulate Wnt signalling by associating with
Kremen1 and 2 to form a complex which regulates internalisation of Lrp [50]. Dkks are critical during
development, and forced expression of Dkk1 in the mouse intestine inhibits epithelial cell proliferation
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and results in a loss of stem cells, highlighting the importance of Wnt signalling in intestinal stem
cells [51,52].
4.4. R-Spondin & the E3 Ligases (Rnf43 & Znrf3)
R-Spondin (R-Spo) proteins are potent agonists of Wnt signalling, but only in the presence
of Wnt ligands [53]. There are four R-Spo proteins in the vertebrate genome, R-Spo1, 2, 3 and 4.
These excreted proteins are characterised by two N-terminal furin domains, a thrombospondin domain
in the centre of the protein and a positively charged C-terminal region [54]. Gene expression and
co-immunoprecipitation analysis revealed that Lgr proteins form a complex with other Wnt receptor
components including Fzd and Lrp5/6, suggesting a potential role as a Wnt receptor [55,56]. It was
subsequently shown that tagged R-Spo1 can bind to Lgr4, -5, and -6 in HEK293 and Ls174 cells.
In support of an interaction between R-Spo and Lgr, R-Spo/Lgr complexes are revoked following Lgr4
or 5 deletions [55,56].
The highly related transmembrane E3 ubiquitin ligases, ZNRF3 and RNF43, act as negative
regulators of canonical Wnt signalling that are integral to R-Spo/Lgr Wnt potentiation [57,58].
Both ZNRF3 and RNF43 were identified from gene expression profiling to discover genes that positively
correlated with known negative regulators of Wnt signalling, such as Axin2 or Dkk-1 [57]. In common
with other Wnt antagonists, including Axin2 and Dkk, ZNR43 and RNF43 are also Wnt target genes [57].
ZNRF3 regulates Wnt signalling by ubiquitylating Fzd-Lrp receptor complexes and thus targeting
them for internalisation and proteasomal degradation [57]. It has also been demonstrated that R-Spo
can induce membrane clearance of ZNRF3 through ZNRF3-Lgr4 dimerisation, thus leading to an
accumulation of Wnt receptors on the cell surface [57,59]. These findings support a model where in
the absence of R-Spo, ZNRF3 ubiquitylates Fzd and promotes the degradation of Fzd-LRP6 complex,
thus keeping Wnt signalling to low levels. However, in the presence of R-Spo, an interaction between
Lgr4 and ZNRF3, via R-Spo Furin domains (1 & 2), leads to the clearance of ZNRF3, allowing Fzd/LRP6
to stabilise and accumulate at the membrane to enhance canonical Wnt signalling [57,59] (Figure 1).
In addition to its important role in regulating canonical Wnt signalling, R-Spo3, is able to regulate
the Wnt/PCP pathway [56]. R-Spo3 forms a complex with Fzd7 to transmit Wnt5a signals by inducing
Sdc4-dependent, clathrin-mediated endocytosis during development (Table 1 and Figure 1). These data
support a model whereby internalisation of the Wnt/receptor complex is an important mechanism by
which R-Spondins promote Wnt/PCP signalling [60].
Table 1. List of proteins which are shown to associate with Fzd7.
Protein Tissue/Cells InteractionInterface Biological Process
Wnt Pathway
Activation Reference
Wg 293T cells CRD Segment polarity β-catenin [61]
Wnt2b 293T cells CRD Intestinal stem cellniche β-catenin [62]
Wnt3a 293T, Huh7 &HepG2 cells CRD
Intestinal stem cell
niche, HCC cell
proliferation and
migration
β-catenin [62,63]
Wnt5a
Mouse
fibroblasts
(L cells)
CRD Cell migration PCP & Calcium [20]
Wnt7a Skeletal muscle CRD Satellite stem cellmaintenance PCP [21]
Wnt8b Xenopus CRD Xenopus development β-catenin & PCP [22]
Wnt9b Embryonicchicken liver CRD
Hepatocyte
morphogenesis and
maturation
β-catenin [64]
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Table 1. Cont.
Protein Tissue/Cells InteractionInterface Biological Process
Wnt Pathway
Activation Reference
Wnt11
Human
embryonic
stem cells,
embryonic
chick
CRD
Mesoderm lineage
specification, neural
crest migration
PCP & Calcium [23,24]
Fzd1 293T cells 7TMdomain Oligomerisation in ER Not determined [65]
Fzd2 293T cells 7TMdomain Oligomerisation in ER Not determined [65]
Fzd4 293T cells 7TMdomain Oligomerisation in ER Not determined [65]
Fzd7 293T cells 7TMdomain Oligomerisation in ER Not determined [65]
Fzd9 293T cells 7TMdomain Oligomerisation in ER Not determined [65]
R-Spo3 Xenopus Co-localise
Receptor complex
endocytosis during
Gastrulation
PCP [60]
Ror2 L cells CRD Cell migration PCP [20]
Lgr4 LS174T cells Co-localise Wnt signalpotentiation β-catenin [55]
sFRP1 CHO cells CRD Cell migration PCP [66]
Ryk Xenopus Co-localise Convergent extension PCP [67]
Sdc4 Xenopus Co-localise
Receptor complex
endocytosis during
Gastrulation
PCP [60]
PSD-95
Yeast
two-hybrid
screen
PDZ
domain Not determined Not determined [68]
Magi3
Yeast
two-hybrid
screen, HEK293
cells
C-terminal Not determined PCP [69]
Sap97
Yeast
two-hybrid
screen
C-terminal Not determined Not determined [68]
Dvl Xenopus
C-terminal
(PDZ
domain)
Convergent extension β-catenin & PCP [20,22,67]
PI3K Skeletal muscle Notdetermined
Satellite stem cell
expansion and
myofibre hypertrophy
PCP [21]
PKN1 293T & A375cells
Plasma
membrane
Inhibits β-catenin
phosphorylation β-catenin [70]
G-Proteins
(Gpa1/Gαs)
Yeast
two-hybrid
screen
C-terminal Not determined MAPK [71]
5. The Wnt Receptor as a Therapeutic Target in Cancer
A vast body of research data exists on the cytoplasmic events involved in Wnt signalling [72] but
only relatively recently have the Wnt receptors that transmit these signals began to attract more interest.
This is due, in part, to the observations made in the 1990’s that the cytoplasmic components of Wnt
signalling are often mutated in many different cancers, thus resulting in more intensive research into
their function and potential as targets for therapeutic intervention. For example, it is now established
that Apc is mutated in 80%–90% of colorectal tumours [73]. As such, strategies to target the Wnt
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receptor complex in cancers harbouring mutations to downstream Wnt signalling components, e.g.,
Apc in colorectal tumours, appeared counter-intuitive. However, in 2002, observations from Ron Smits
lab based on the location of mutations occurring naturally in the Apc gene led them to propose the “just
right” or Goldilocks model of Wnt signalling in cancer which proposes an optimal, but not excessive,
level of Wnt pathway activation to transform cells, suggestive of constrained Wnt activation [74].
Furthermore, a surprising result from Ian Tomlinson’s group also supported the Goldilocks model,
in which a novel Apc mutant mouse (Apc1322T) developed severe intestinal polyposis associated
with weaker Wnt pathway activation when compared to ApcMin/+ mice (which are predisposed to
develop intestinal tumours after loss of heterozygosity results in Apc mutations on both alleles [75,76].
Conversely, work from Alan Clarke’s lab demonstrated that ApcMin mice deficient for the Wnt target
gene Cited1 developed significantly less tumours and had extended life span compared to their ApcMin,
Cited1 proficient littermates [77]. Further analysis of this phenotype revealed that Cited1 deficient
mice displayed elevated levels of Wnt signalling during tumourigenesis, which became cytotoxic and
induced cell death, consequently resulting in the development of fewer intestinal tumours [77]. This is
consistent with many in vitro studies demonstrating that high levels of Wnt can induce cell death,
but was the first to observe this phenotype during tumourigenesis in vivo. Conversely, co-deletion
of the Wnt target gene c-Myc and Apc is sufficient to inhibit all intestinal tumourigenic phenotypes,
which is due to restoration of Wnt signaling back to wild type levels. [78]. This concept, that Wnt
signalling is not 100% activated when Apc is mutated in cancer cells, reveals a therapeutic window
whereby targeting the Wnt receptor can still reduce the level of Wnt signalling even in cells which
have mutations in Apc [78].
The Goldilocks model also requires that the degradation complex is still partially functional even
in cells with mutations in Apc (a critical component of the complex that phosphorylates β-catenin
and targets it for degradation), and thus leaves open the possibility that Wnt signalling can be
modified in cells with Apc mutations. Indeed, several publications in the mid 2000’s demonstrated
that manipulation of factors up-stream of the degradation complex, at the level of the Wnt ligand
and receptor, could alter the response of colorectal cancer cells even if they contained mutations to
APC. For example, the promoter regions of SFRPs [79–81] and WIF1 [82] are hypermethylated and
consequently down-regulated in the very early stages of gastrointestinal cancer, with the methylation
status of certain SFRPs serving as biomarkers for cancer detection and progression [14,83]. The Fzd7
extracellular domain has also been shown to potently inhibit the growth of APC mutant CRC tumour
cells in a mouse xenograft model [84]. Furthermore, exogenous Wnt originating from tumour associated
myofibroblasts was not only capable of maintaining cancer stem cell function and clonality in cells
isolated from human colon tumours, but was also able to promote the stemness and clonality of
non-cancer stem cells [85]. Importantly, these data indicate that the Wnt receptor complex is not
redundant in cancers that have mutations to cytoplasmic Wnt regulators, but in fact still play an
active role to promote cancer initiation and growth. As detailed below, many cancers in addition to
gastrointestinal cancer have now been reported to display hypermethlylation and downregulation of
Wnt ligand/receptor inhibitors such as the SFRP, DKK and WIF, and many also display elevated levels
of FZD receptors, suggesting that activation of Wnt signalling via the receptor is involved in driving
cancer growth. Furthermore, expression of Wnt and FZD’s are often up-regulated in diverse cancers as
detailed below [79,86–88].
6. Frizzled 7
The Fzd genes were originally discovered along with several other genes including dishevelled
(dsh), fuzzy (fy) and multiple wing hairs (mwh), that affect planar cell polarity in Drosophila, which
was monitored by changes to the orientation of hairs on the wings surface. As such mutations in Fzd
genes resulted in changes to the PCP pathway, which disrupted the orientation of wing hairs into a
whorl-like appearance [89,90]. Since then, Fzd genes have been found in a diverse range of organisms,
from sponges [91] and hydra [92] to vertebrates [93], and have been experimentally demonstrated to
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be receptors for Wnt ligands [61,94]. Human FZD7 was first identified and characterised in 1998 [1],
and was also discovered to be upregulated in oesophageal cancer by a different group in the same
year, who named it FzE3 [95].
Following the discovery of Fzd genes in Drosophila, intense research into the identification,
expression and function of Wnt and Fzd homologues during development in other model organisms
such as Xenopus, C. elgans and vertebrates (mice) ensued. Indeed, the successful cloning of Xenopus
Fzd7 (Xfz7) by Wheeler and Hoppler [96] facilitated a surge in the understanding of evolutionary
conserved roles for Wnt/Fzd7 signalling during various developmental and adult processes such as
neural crest induction [97], gastrulation [98] and intestinal homeostasis [62]. This is particularly well
exemplified in the gut. For example, the gastric tube of hydra, which is separated into endodermal
and ectodermal layers, express Wnt signalling orthologues such as β-catenin [99], Fzd7, Gsk-3β, Dvl,
Apc, and Axin from the Wnt/β-catenin pathway [92,100] and Van Gogh, Flamingo and JNK from the
Wnt/PCP pathway [101] along an oral-aboral axis during gastrulation [102]. The organisation and
coordinated balance of cell renewal and movement of epithelial and interstitial cells throughout
the gastric tube is regulated by Wnt/Fzd signalling [103–105]. Of note, when compared to the ten
mammalian Fzd family members, the hydra Fzd shares closest homology with Fzd7 (and Drosophila
Fzd2) [92,106], which suggests an essential role for Fzd7 in regulating cell differentiation, proliferation
and the establishment and homeostasis of three-dimensional gut tissue architecture, which has been
maintained throughout millions of years of evolution as it is also critical in higher organisms [62].
Indeed, Xfz7 has been shown to regulate the coordinated convergent extension movement
of cells [67], tissue separation [98] and dorsal axis specification [107] during gastrulation in
developing Xenopus laevis. Furthermore, the absolute requirement for canonical Wnt signalling in the
developing and adult intestinal epithelium implicates a pivotal role for Fzd receptors [51,52,108,109].
In the mammalian intestinal epithelium, Fzd7 expression is restricted to the stem cell/progenitor
compartment, the crypts of Lieberkühn, suggesting a role in Wnt signal transduction to intestinal
stem cells [62,110]. As such, Fzd7 has been recently shown to be the Fzd receptor responsible for
transmitting key Wnt signals to intestinal stem cells, facilitating intestinal stem cell maintenance,
epithelial homeostasis and regeneration following DNA damage [62].
Fzd7´/´ mice are viable and have a mild truncation and kink in the tail [111], which is reminiscent
of the loop-tail phenotype in PCP mutant mice [112–115], suggesting Fzd7 partially regulates PCP
signalling during development. However, as Fzd7´/´ mice do not have an intestinal phenotype, this
suggests that PCP signalling via Fzd7 is less important during intestinal development and homeostasis.
Furthermore, canonical Wnt signalling is absolutely required during intestinal development and
homeostasis [108]. Therefore regulation of canonical Wnt signalling via Fzd7 must be functionally
compensated by other frizzled receptors in Fzd7´/´ mice during development and homeostasis of
the intestine. Fzd2 has been demonstrated to compensate for loss of Fzd7 during development,
since compound Fzd2´/´; Fzd7´/´ mice die at E10.5, whilst Fzd1´/´; Fzd7´/´ are healthy and
fertile [111]. Although genetic deficiency of Fzd7 can be tolerated during development and homeostasis
of the intestine, surprisingly, acute genetic deletion of Fzd7 is deleterious in intestinal stem cells [62].
This could be due to a combination of factors.
Firstly, in Fzd7´/´ mice, the compensation mechanism using Fzd2 in the absence of Fzd7, has been
occurring all through development and thus the system is fully established in the adult intestinal
epithelium. This is a very different scenario from acute, conditional deletion which would result
in significant stress for intestinal stem cells, which require Wnt signalling, possibly resulting in a
different response from that of continued absence of Fzd7 from the beginning of conception as in a
Fzd7´/´ mouse.
Secondly, conditional deletion of Fzd7 in the intestinal epithelium triggers rapid repopulation of
the epithelium with Fzd7 proficient cells, which is not possible in a Fzd7´/´ mouse [62]. Conditional
deletion of other genes in the intestine, including c-Myc [116] and Chk1 [117], also trigger rapid
repopulation, and thus it seems this mechanism is a sufficient safe-guard to protect intestinal stem
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cells if they experience the deletion of a critical gene such as Fzd7 [62], rather than relying on Fzd2 to
transmit the crucial Wnt signals. Thirdly, the capacity of the intestinal epithelium to regenerate after
irradiation-induced DNA damage is markedly reduced in Fzd7´/´ mice, however regeneration does
recover and is associated with an increased expression of Fzd2 and Fzd1, suggesting that if repopulation
with Fzd7 proficient cells is not possible (as in a Fzd7´/´ mouse), then compensation with other Fzd
genes can occur [62].
Fzd7 is able to modulate the transmission of both canonical and non-canonical Wnt pathways.
There are many examples of Fzd7 transmitting canonical Wnt signalling in several tissues during
development, homeostasis and disease in many organisms including humans [118]. This occurs via
Fzd7 associating with Lgr4/5 [55] and a Wnt ligand such as Wnt3, and is greatly enhanced in the
presence of R-Spondin which prevents Rnf43 mediated degradation of the Fzd7 receptor complex [119].
In the neural crest, Fzd7/Wn6 induces epithelialisation of the somites via β-catenin [120], while
Fzd7/Wnt11 orchestrates neural crest cell migration via the PCP and Ca2+ pathways [24].
Another layer of complexity that can influence the activation of specific Wnt/Fzd pathways
is the subcellular localisation of Fzd receptors. This was formally demonstrated in experiments
overexpressing chimeric DFzd1 and DFzd2 proteins in the Drosophila wing imaginal disc epithelium.
This study revealed that the intracellular C-terminal of Fzd proteins is responsible for directing the
localisation of specific Fzd receptors within an apical-basal axis, which in turn direct either PCP (apical)
or canonical (basal) Wnt signalling [121]. Of note, the recent visualisation of a short-range Wnt gradient
operating in the intestinal stem cell niche identified Wnt3, a prototypical canonical Wnt ligand, to be
expressed on the baso-lateral membrane of Paneth cells, which is received by Fzd receptors on adjacent
Lgr5+ stem cells [10]. This finding is consistent with observations that Fzd7 is expressed in Lgr5+
intestinal stem cells [62,122] on the baso-lateral membrane [123], and is required for their function
in vivo [62]. It will be of future interest to investigate whether the intracellular C-terminal of Fzd7 is
required for its baso-lateral localisation and how this may impact on intestinal stem cell function.
During Xenopus development Fzd7 can form a complex with R-Spo3 to transmit Wnt5a signals and
activate PCP signalling by inducing Sdc4-dependent, clathrin-mediated endocytosis [60]. These data
support a model whereby internalisation of the Wnt/receptor complex is an important mechanism by
which R-Spondins promote Wnt signalling.
Fzd7 can also co-operate with Ryk co-receptors to transmit Wnt 11-mediated signals via
β-arrestin2-dependant endocytosis and JNK in convergent extension during Xenopus development [67].
Furthermore, low levels of β-catenin and non-canonical JNK (PCP) signalling can both be activated
by Fzd7 to regulate foregut fate and proliferation during Xenopus development [124]. Fzd7 has also
been shown to regulate PKC, and its translocation to the cell membrane during Xenopus gastrulation,
suggesting it can regulate the Ca2+ pathway [98]. Recently it has also been demonstrated that Fzd7 (and
Fzd1, Fzd2 and Fzd6) is able to directly interact with G proteins to activate MAPK (PCP) signalling [71].
Finally, the specification and expansion of human embryonic stem cells (hESCs) during
development relies on controlled spatial and temporal Wnt signalling. Meta-analysis of 38 publications
studying gene signatures of hESCs identified that FZD7 is consistently expressed highlighting that
FZD7 is the predominant FZ receptor in many stem cell populations [125]. This was also observed
at the protein and transcriptome level [126]. Indeed, canonical Wnt signalling via Wnt3a and FZD7
promote the proliferation of hESCs and subsequent knockdown of FZD7 has been shown to induce
hESC differentiation [127,128]. However, interestingly, in the same model system, non-canonical Wnt
signalling activated by Wnt11 and FZD7, is sufficient to direct hESCs from pluripotency towards
mesodermal lineage specification [23]. Collectively, these studies demonstrate not only the promiscuity
of Wnt/Fzd interactions, but how subtle changes in the availability of Wnt ligands and/or receptor
components can direct different cellular outcomes.
The Wnt-Fzd interaction is promiscuous, with a single Wnt able to bind multiple Fzd proteins,
and vice versa, to activate canonical and/or non-canonical Wnt signalling. Successful crystallisation
of Xenopus Wnt8 bound to Fzd8 CRD revealed two distinct residue moieties that facilitate Wnt/Fzd
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binding [129]. One is via a palmitoleic acid lipid group found on the Wnt protein that projects into a
deep groove in the Fzd8 CRD. The second is a conserved finger-like projection that forms a hydrophobic
amino acid interface with a depression in the opposite side of the Fzd8 CRD [129]. The authors of this
important work also conclude that the binding chemistry of the Wnt/Fzd interaction strongly suggests
that mono-specificity is not compatible and thus it is highly unlikely that a restricted ligand-receptor
matched code exists [129].
The Wnt-Fzd structure reveals the precision with which Wnt binds Fzd and provides evidence
for complex oligomerisation with co-receptors to transduce signals to cytoplasmic signal transducers,
most notably, Dvl [129]. The Fzd receptors are thought to homo- or hetero-dimerise in order to
signal, which adds another level of complexity to Wnt/Fzd signalling [40,129]. This notion, based
on the crystal structure of the CRD region, is supported by Fzd oligomerisation assays, which show
that each Fzd tested (Fzd1, 2, 4, 7, 9) homo-oligomerise, and that some Fzd receptors are able to
hetero-oligomerise (e.g., Fzd1, 2 & 7). Notably, Fzd7 could oligomerise with each Fzd tested [65], and is
also able to associate with several co-receptors which may help explain why Fzd7 is the only member
of the Fzd family that has been demonstrated to activate each branch of the pathway: Wnt/β-catenin
pathway [107,130], the PCP pathway [22,131] and the Wnt/Ca2+ pathway [98].
This promiscuity of Fzd7 to associate with different co-receptors and regulate both arms of the
Wnt pathway may explain its frequent up-regulation in many different cancers to drive tumour growth,
as both pathways are implicated in cancer. Although a variety of proteins have been discovered to
bind Fzd7, not all of them have been functionally characterised [70] (Table 1 listing the different
proteins that Fzd7 can bind to and the signalling output). However Fzd7 is not unique in its ability
to activate canonical and non-canonical pathways, with examples also published for other Fzd’s.
For example, Fzd5/Wnt5a activates the Ca2+ pathway in melanoma and is associated with a more
aggressive phenotype [132], whilst in the developing retina Fzd5 signals via β-catenin [133].
These exciting developments have spawned a new focus in cancer research to target the Wnt
ligand/receptor complex as a potentially therapeutic strategy to treat several different cancers detailed
in the sections below.
Regulation of Fzd7
Gene regulation is governed by a complex network of cellular mechanisms, which can be
modulated at every step. As such, the ever-expanding interplay between signaling pathways,
transcription factors and post-transcriptional modifiers demonstrates that the expression of a single
gene is not exclusively governed by a single factor. Indeed several recent studies have demonstrated
the expression of Fzd7 to be regulated by multiple highly conserved signalling pathways and
post-transcriptional modifiers (miRNAs). Wnt/β-catenin signaling is one of the key signalling
pathways shown to regulate FZD7 expression, as FZD7 expression is increased in human embryonic
carcinoma cells following exposure to Wnt3a conditioned medium [87]. In addition, the FZD7
promoter houses putative TCF binding sites, confirming its regulation by Wnt/β-catenin signaling [87].
Wnt/β-catenin-mediated regulation of FZD7 is further supported by findings demonstrating the
activation and repression of a FZD7 promoter-driven luciferase reporter in response to β-catenin
stimulation and inhibition respectively [88]. However, given the increasing complexity of crosstalk
between signalling pathways, it’s of little surprise that Fzd7 expression is regulated by more than just
Wnt signalling. For instance, unpublished data from our own lab indicates that Fzd7 is a transcriptional
target of Jak/Stat3 signalling [123]. These findings are corroborated by observations made in articular
chondrocytes, demonstrating a reduction in FZD7 expression following pharmacological inhibition
(AG490) of JAK2 [134]. More recently, the Notch signaling pathway, specifically NOTCH3, was shown
to regulate the expression of FZD7 in human mammary epithelial cells [135]. Further analysis revealed
FZD7 to be expressed predominantly by luminal progenitor cells, which is hypothesised to regulate
luminal cell differentiation through a NOTCH3-FZD7 signalling axis [135].
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Furthermore, microRNAs (miRNAs or miRs), small non-coding RNAs that influence
post-transcriptional gene expression through imperfect binding to the 3’ UTR of mRNA, play important
roles in development and disease, placing them as potential therapeutic targets. As such, several
miRNAs have been identified to influence the activation of Wnt signalling via regulation of Fzd7
expression. For instance, miRNA-206 is a critical myogenic regulation factor required for correct
skeletal muscle development and differentiation [136]. Subsequent algorithmic and bioinformatic
analysis of gene expression databases reveal Fzd7 to be a direct target of miRNA-206 [137]. As such,
overexpression of Fzd7 induces increased proliferation and abnormal myoblast differentiation [137].
These findings are supported by previous studies demonstrating a central role for Fzd7 in skeletal stem
cell maintenance in muscular dystrophy animal models via activation of Akt/mTOR signalling [21].
Wnt signalling is a critical signaling pathway during the development, homeostasis and
regeneration of the intestinal epithelium [8,62,138]. Recent research has identified several miRNAs,
including miRNA-222, that influence intestinal epithelial biology [139]. Intestinal regeneration was
significantly impaired in a novel miRNA-222 overexpressing transgenic mouse, which was associated
with impaired Wnt activation, through downregulation of Fzd7 [140]. Indeed, Fzd7 was subsequently
shown to be a direct target of miRNA-222, thus revealing induction of miRNA-222 negatively regulates
intestinal regeneration through suppressing the expression of Fzd7 [140]. These data are strongly
supported by recent work showing intestinal regeneration to be significantly impaired in Fzd7´/´
mice [62].
Likewise, miRNAs have been shown to influence the expression of Fzd7 in several different
cancers, and associated with reduced tumour growth, which are discussed in the relevant cancer
sections below. However, recently Li et al. uncovered a two-faceted role for miRNA-126 in acute
myeloid leukemia (AML), demonstrating that either overexpression or knockout of miRNA-126 could
promote AML via inducing the expression of oncogenic fusion genes [141]. Interestingly, knockdown of
miRNA-126 repressed the expression of tumour suppressor genes ERRFI1 and SPRED1, but increased
Wnt pathway activation via increased FZD7 expression. This resulted in accelerated AML progession,
however, cells were sensitised to standard chemotherapy agents [141]. Collectively, these studies
reveal some of the factors regulating Fzd7 expression, and illustrate its importance in several biological
contexts, from development and regeneration through to homeostasis and cancer.
7. Intestinal Cancer
Wnt signalling has been recognised as an important driver of intestinal cancer for many
years. Mutations to APC were first observed in colon tumours of FAP (familial adenomatous
polyposis) patients in the 1990’s [142–144]. Subsequent studies demonstrated that Apc is a potent
tumour suppressor; a mutagenesis screen in mice identified that mutation to Apc caused multiple
intestinal adenoma’s (these mice were called ApcMin/+) [75,145], whilst conditional truncation of Apc
throughout the intestine using transgenic mice resulted in rapid uncontrolled proliferation similar
to tumourigenesis [146,147]. Furthermore, intestinal stem cells, marked by the Wnt target gene Lgr5
were identified as the cell of origin for intestinal cancer, as truncation of Apc specifically in Lgr5+
cells resulted in widespread, rapid, development of adenoma’s throughout the small intestine and
colon [148]. Although β-catenin mutations are observed at much lower frequencies than Apc in intestinal
tumours (~5% compared to ~75%) [3], conditional activation of β-catenin is sufficient to induce
tumourigenesis in the mouse intestine [149,150], supporting the model of cytoplasmic Wnt signalling
components as regulators of intestinal cancer. Indeed, truncating mutations in Apc or oncogenic
mutation in β-catenin are mutually exclusive but appear to be obligatory initiating steps for CRC [151].
Thus, intestinal tumourigenesis requires constitutive activation of the canonical Wnt pathway, although
the aetiology of APC and β-catenin mediated intestinal cancer is different [151,152]. Oncogenic
mutations in β-catenin are more common in intestinal tumours with microsatellite instability [3].
Intriguingly, APC truncation may provide the genetic make-up for additional regulation by the Wnt
pathway (reviewed in [106] and papers cited within). For example, LEF-1 over-expression alone
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is sufficient to induce EMT in a developmental context, but both LEF-1 over-expression and APC
truncation are required to induce EMT in a colon cancer setting. Furthermore, restoring full length
APC is sufficient to abrogate tumour growth in human colon cancer cells in vitro [153], or using a
mouse model which allows deletion and restoration of Apc in vivo [154].
Due to the high frequency of Apc mutations observed in intestinal cancer it was assumed that the
Wnt receptor complex would not be important in regulating Wnt activity in this setting. However,
as described above, SFRPs, WIF-1 and DKK1 are often hypermethylated and downregulated very
early in intestinal cancer suggesting the Wnt receptor complex does play a role [79,80,155]. Indeed
the Wnt agonists RSPO2 and RSPO3 are fused in 10% of human colon tumours and act to potentiate
Wnt signalling [156]. As such, the treatment of human patient-derived colon tumour xenografts with
specific monoclonal antibodies generated against RSPO family members (anti-RSPO) have shown
promising growth inhibition and reduced Wnt/β-catenin signalling when used in combination with
standard chemotherapy [157]. In addition, loss-of-function (LOF) mutations to the E3 family ligases
ZNRF3 and RNF43, which serve to negatively regulate Fzd receptor turnover, are commonly observed
in human colon tumour biopsies [3]. Such tumours are predicted to be hypersensitive to Wnt signalling
through the stabilisation of Fzd receptors [58].
Several FZD receptors are over expressed in human intestinal tumours and cell lines, including
FZD3, FZD6 and FZD7 [1,106,158]. Inhibition of FZD7 using a dominant negative extracellular domain
is able to block the growth of human colon cancer cells in vitro and in xenograft experiments with
stably transfected SK-CO-1 cells, which harbour mutations to APC [84]. Recently Fzd7 has also been
demonstrated to be the predominant Wnt receptor required to transmit Wnt signalling (via Wnt 3 or 2b)
in intestinal Lgr5+ stem cells during homeostasis and regeneration [62]. Conditional deletion of Fzd7
in intestinal organoids resulted in crypt atrophy and organoid death, whilst conditional deletion of
Fzd7 specifically in the Lgr5+ intestinal stem cells triggered rapid epithelial repopulation in transgenic
mice [62], demonstrating that Fzd7 is critical for intestinal stem cell function. As Lgr5+ stem cells are
the cell of origin for intestinal cancer and also a marker of intestinal cancer stem cells, this data opens
new avenues of research to determine the therapeutic benefit of inhibiting Fzd7 to specifically target
these cells.
In addition to its role in the very first stages of tumourigenesis, Wnt signalling is also implicated
in the progression and invasion of intestinal tumours. Analysis of gene expression in the metastatic
potential of human primary colon cancers identified several Wnt target genes to be important, including
BAMBI, BOP1, CKS2 and NFIL3. Inhibition of these Wnt target genes with shRNA was able to reduce
migration and invasion in vitro and also completely block the formation of secondary liver tumours in
mice following intrasplenic injection of SW620 cells transduced with the corresponding shRNA [159].
Fzd7 also plays an important role during metastasis by regulating the critical stages in which
epithelial cancer cells transition into mesenchymal cells when leaving the primary tumour (EMT),
and then from mesenchymal to epithelial (MET) at the secondary site [152,160–163]. Expression of
a dominant negative FZD7 in human SK-CO-1 cells blocked their growth in xenograft experiments
and induced morphological changes suggesting that FZD7 promotes MET [84]. The role of Fzd7
during MET was further supported in experiments using a novel model of tumour morphogenesis
termed LIM1836-Mph cells (human colon cancer cells) which go through cycles of EMT and MET
in vitro [158]. MET in these cells is associated with a sharp increase in nuclear β-catenin, and treatment
with FZD7 specific shRNA is able to inhibit MET suggesting FZD7 regulates canonical Wnt signalling
in this process [158]. On the other hand, nuclear β-catenin was very low in migrating LIM1836-Mph
cells, however FZD7 shRNA could also inhibit migration of these cells suggesting Fzd7 mediates
non-canonical signalling of migrating colon cancer cells [158]. Indeed, this was subsequently formally
demonstrated by Ueno and colleagues who showed FZD7-mediated vertebrate PCP pathway is
involved in colon cancer cell migration [164].
Furthermore, high-throughput screening for miRNAs implicated in human carcinomas has
revealed significant downregulation of miR-23b in human colon cancers, which promotes metastasis,
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tumour growth, invasion and angiogenesis [165]. Subsequent investigations demonstrate that FZD7
is a direct regulatory target of miR-23b and targeted inhibition of FZD7 or miR-23b can significantly
reduce migration, growth and angiogenesis in human colon cancer cells [165].
8. Hepatocellular Carcinoma
By far the most characterised cancer with relation to FZD7 is Hepatocellular carcinoma (HCC).
Between 40%–70% of HCC display elevated nuclear β-catenin [166] suggesting that canonical Wnt
signalling maybe important, and it is especially high in HCC associated with Hepatitis B virus
(HBV) infection [167]. Although intracellular components of the Wnt pathway such as Axin1 and
β-catenin are mutated in some cases of HCC, they are not sufficient in number to account for the high
frequency of Wnt pathway activation observed, suggesting activation of the pathway at the level of
the ligand/receptor. Indeed, several Wnt ligands are overexpressed in HCC, including Wnt1/3/4/5a
and 10b, whilst Wnt antagonists sFRP1/4/5, Wif1, Dkk3, Dkk4 are frequently reduced [168]. Many of
these genes have been functionally demonstrated to regulate tumour growth, thus highlighting that
HCC can be modulated by Wnt signalling at the level of the receptor [168]. Indeed, serum levels of
Dkk1 can be used to diagnose HCC and differentiate HCC from HBV infection [169].
FZD7 is frequently over expressed in HCC, especially in patients infected with HBV [167], and has
been shown to interact with Wnt3a to transmit canonical Wnt signalling in HCC [63]. One strategy to
treat HCC via manipulation of FZD7 may involve the use of soluble peptide fragments to antagonise
FZD7 signalling. For instance, HCC cell lines (HepG2 and Huh7) treated with a recombinant soluble
FZD7 (sFZD7) peptide, which contains the extracellular domain of FZD7, inhibits Wnt/β-catenin
signalling and decreases cell proliferation and viability (without effecting normal hepatocytes) [170].
The effects of sFzd7 on abating HCC tumourigenicity were accomplished by the competitive binding
of the Fzd7 extracellular CRD with Wnt3, which activates the canonical Wnt signalling pathway [170].
This is consistent with results observed in colon cancer cells using the same strategy [84].
Post transcriptional control of FZD7 is also observed in HCC. The expression of miR199a is
frequently downregulated in human liver tumours, and associated with poor clinical outcome.
Experimental overexpression of miR199a in human HepG2 HCC cells was able to repress cancer
growth in vitro and in vivo, and was associated with inhibition of FZD7 [171].
FZD7 is overexpressed in the surrounding periportal and dysplastic liver suggesting it may
be important during early stages of HCC [63]. However, the precise role of Wnt signalling during
the very early stages of the disease are still the subject of debate as conditional activation of Wnt
signalling in transgenic mouse models reveals that elevated Wnt signalling causes hepatomegaly and
disorganisation of liver zonation, but does not result in the development of tumours [172,173]. It seems
therefore that deregulated Wnt signalling acts more to promote HCC in co-operation with other
oncogenic pathways such as AKT, MET, H-RAS, insulin receptor substrate-1 and chemical mutagens.
This does not make targeting FZD7 for the treatment of HCC any less attractive as mono-therapies
have failed to provide any robust clinical outcomes and co-treatments targeting multiple pathways is
now the focus of most targeted therapy approaches.
9. Gastric Cancer
Wnt signalling is emerging as an important oncogenic pathway in gastric cancer (GC). The recent
Cancer Genome Atlas paper, which analysed 295 primary gastric adenocarcinomas, identified that
APC is the 6th most frequently mutated gene in the non-hypermutated gastric tumours (over three
times more frequent than the hypermutated subgroup which does not contain APC mutations).
When combined with gain-of-function mutations in β-catenin, the Wnt pathway is found to be
activated in over 10% of GCs [174]. These observations are consistent with a second paper investigating
molecular profiling of GC in Nature Genetics in which the authors conclude that aberrant Wnt/β-catenin
signalling plays an important role in gastric adenoma [175]. Deregulation of Wnt signalling by
conditional deletion of all 4 copies of Gsk3 (both α and β isoforms) was able to induce formation
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of gastric tumours in mice, thus providing functional proof that activation of Wnt is able to trigger
tumourigenesis in the gastric epithelium in vivo [176].
Components that are known to be associated with signalling via FZD7 are strongly implicated
in GC. For example, it has been shown extracellular secreted Wnt antagonists (sFRP and Dkk)
are frequently epigenetically silenced through promoter hyper-methylation [81,177]. Critically,
exogenous re-introduction of Wnt pathway inhibitors, such as sFRP1, 2 or 5 and Dkk1, or reversing
promoter methylation can significantly limit and reduce in vitro tumourgenicity and tumour xenograft
burden of Wnt pathway-activated gastric cancer models by means of attenuating Wnt/β-catenin
signalling [81,177,178]. Importantly, these studies demonstrate (a) activated Wnt signalling is
sufficient to drive gastric tumourigenesis and (b) provide proof-of-principle that modulation of
extracellular/upstream signalling components can impact on Wnt pathway output irrespective of
intracellular/downstream mutations that would otherwise drive positive feed-forward Wnt signalling.
Furthermore, the fact that sFRPs and Dkks act by inhibiting Wnt/FZD signalling implies a role for
Wnt/FZD in tumourigenesis of GC.
There are several reports suggesting that the non-canonical Wnt pathway is active in GC.
RHOA, a downstream component of non-canonical Wnt signalling and FZD7 [179], is upregulated in
GC [174,180], whilst ROR1, a tyrosine kinase like receptor able to transmit non-canonical Wnt5a
signals [181], is phosphorylated in HS746T human gastric cancer cells, via a Met dependant
mechanism [31]. Wnt5a, which primarily activates the non-canonical pathway, is up-regulated in
human gastric tumours, however, this is not observed in cultured human GC cell lines (OKAJIMA,
TMK1, MKN7, MKN28, MKN74 and KATOIII) suggesting the source of Wnt5a is from stromal
cells [182]. Similarly, Wnt5a and Wnt2 were found to be significantly up-regulated in colon cancer
associated macrophages [183], illustrating that Wnt signals can originate from outside the tumour
cells themselves.
Several reports demonstrate that FZD7 expression is upregulated in GC, with high expression
associated with poor clinical outcome [184–186]. However, mutations in RNF43, an E3 ubiquitin ligase
that regulates FZD receptor turnover and therefore activate Wnt signalling, are frequently observed
in GC [174]. This data, together with methylation of SFRPs (frequently observed in GC) identifies
additional mechanisms that increase Wnt signalling, which cannot be identified by transcriptional and
mutational analysis of FZD’s itself, and suggests that the importance of FZD in GC could presently be
underestimated. FZD7 expression is also increased in a side population of cells isolated from GC cell
lines, which were found to have increased cancer stem cell properties, supporting a role for FZD7 in
promoting GC [186]. Indeed, conditional deletion of Fzd7 is able to inhibit the growth of gastric cancer
cells and in mouse models of GC and colony forming assays with human GC cells [123].
Finally, the strong association between aberrant Wnt signaling and H. pylori-induced gastric
tumourigenesis, implicates a role for Fzd receptors to promote Wnt signalling in gastric cancer. As such,
recent research has shown FZD7 to be highly expressed following H. pylori infection and associated
increases in cell proliferation [187]. Subsequent analysis demonstrates FZD7 to be negatively regulated
by miRNA-27b, which when overexpressed is sufficient to inhibit the expression of FZD7 and reduce
gastric cancer cell proliferation. Likewise, targeted knockdown (siRNA) of FZD7 in H. pylori-induced
gastric cancer cells effectively phenocopies the effect of miRNA-27b overexpression [187].
10. Breast Cancer
Wnt signalling regulates the development and homeostasis of the breast [188] and is deregulated
in breast cancer. Indeed Wnt1 was first identified as a gene, the ectopic expression of which via pro-viral
insertion, was able to promote mammary tumourigenesis [4]. SFRPs and WIF are frequently methylated
and consequently down regulated in breast cancer leading to activation of the Wnt pathway [189,190].
Similarly, LRP6 overexpression was found in a subtype of ER-negative and HER2-negative breast
tumours [191].
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A screen to analyse which pathways were active in triple negative (TN) breast cancer, identified
that the Wnt pathway was an important driver in this aggressive type of breast cancer and that
FZD7 was often overexpressed [192]. Indeed, knockdown of FZD7 using shRNA was able to inhibit
migration, colony formation and xenograft growth of human MBA-MB-231 TNBC cells which was
associated with reduced canonical Wnt signalling [192].
Furthermore, recent research has revealed a novel mechanism by which FZD7 expression is
regulated in breast cancer cells. SIRT1, an NAD+-dependent deacetylase positively regulates FZD7
mRNA and protein levels, promoting increased cell migration and proliferation [193]. As such, genetic
and/or pharmacological inhibition of SIRT1 significantly reduced FZD7 levels through perturbing
the binding of β-catenin and c-Jun transcription factors to the endogenous FZD7 promoter, reversing
the potent tumourigenic effect of FZD7 overexpression in breast cancer cells [193]. In addition, an
elegant study from Yibin Kang’s group recently demonstrated a separate regulatory mechanism of
FZD7 in human mammary stem cells (MaSCs) and TN breast cancer cells. A specific isoform of the
p63 family, ∆Np63, is commonly expressed in the normal mammary epithelium, where it regulates
MaSCs and when overexpressed is sufficient to transform normal MaSCs to tumour-initiating cells
(TICs) [194]. Gene-set enrichment analysis (GSEA) of ∆Np63/+ MaSCs reveals alterations exclusively
to Wnt signalling, with substantial decreases in Fzd7 and Wnt5a expression, resulting in a significant
reduction in MaSCs [194]. Chromatin immunoprecipitation (ChIP) analysis on wild type MaSCs
demonstrates a strong enrichment of the FZD7 enhancer in p63 bound chromatin, which was further
supported by the activation of a FZD7 enhancer-driven luciferase reporter in response to ∆Np63, thus
demonstrating Fzd7 is a direct target of ∆Np63 [194]. Subsequent overexpression and knockdown
studies targeting ∆Np63 or FZD7 in patient-derived xenografts (PDX) from TN breast tumours
significantly attenuated tumourigenicity, which was associated with a reduction in the number of
TICs [194]. These data demonstrate a pivotal ∆Np63-Fzd7-WNT signalling axis, which may represent
a driving force for the initiation and maintenance of TN breast tumours, thus serving as a potential
target for therapeutic intervention.
11. Ovarian Cancer
As with other cancers, a role for the Wnt signalling pathway at the level of the receptor/ligand
has been suggested from studies on the SFRP genes. SFRP1 SFRP2 and SFRP5 are methylated in
ovarian cancer [195], and experimental overexpression or knockdown, demonstrated that epigenetic
silencing of SFRP5 was related to tumour growth, invasion (via EMT) and chemosensitivity in ovarian
cancer [196].
Ovarian cancer is a heterogenous disease but can be broadly separated into five distinct subtypes
based on molecular characteristics; epithelial-A (Epi-A), Epi-B, mesenchymal (Mes), Stem-A and
Stem-B. FZD7 is upregulated in the Stem-A subgroup of ovarian cancer, which has a poor clinical
outcome [197]. Knockdown of FZD7 using siRNA was able to inhibit proliferation of human ovarian
adenocarcinoma cell lines [179] associated with changes in cell morphology which have also been
observed in colon cancer cells [84].
Interestingly, inhibition of FZD7 in ovarian cancer cells resulted in an increase in the level of
canonical signalling, whilst the non-canonical signalling components including RhoA were slightly
down regulated. These data suggest FZD7 maybe regulating ovarian cancer cell growth via the
Wnt/PCP pathway rather than the canonical pathway, which is upregulated in Stem-A ovarian
tumours [179].
12. Cervical Cancer
Nuclear β-catenin is observed in ~70% of cervical tumours indicating deregulation of Wnt
signalling is common in cervical cancer [198]. However, mutations to APC and β-catenin are rare in
this cancer, suggesting that Wnt signalling could be activated at the level of the receptor in cervical
Cancers 2016, 8, 50 17 of 33
cancer [198]. Indeed, this is supported by studies reporting hypermethylation and downregulation of
DKK-3 [199], WIF-1 [200], SFRP-1, SFRP-2 and SFRP-4 [201] in cervical tumours.
Inhibition of FZD7 using shRNA was able substantially reduce invasion and EMT in HeLa and
SiHa cervical cancer cell lines in vitro [202]. These phenotypes were associated with changes in the
regulation of EMT markers including E-Cadherin, Vimetin and Snail, and also down regulation of
MMP genes which are implicated in invasion. Levels of phosphorylated c-Jun and JNK were also
reduced when FZD7 was inhibited suggesting the PCP pathway maybe involved in transducing
signals downstream of FZD7 in cervical cancer, although no assays were performed to determine
the activation of canonical Wnt signalling [202]. Moreover, subsequent studies from the same lab
demonstrated FZD7 to be a direct target of miRNA-142-3p, which is normally expressed at low levels in
cervical cancer cells. Importantly, restoration of miRNA-142-3p expression significantly reduced FZD7
expression, cell proliferation and invasion, thus identifying miRNA-142-3p and FZD7 as attractive
therapeutic targets for cervical cancer therapy [203].
There is no data to demonstrate that FZD7 is upregulated in cervical cancer, however, as mentioned
above, the role of FZD7 in cancer could be underestimated, as seems the case in cervical cancer, due
to changes in the membrane turnover of FZD7, which will greatly affect the response of a cell to
Wnt ligands.
13. Melanoma
There are conflicting reports on the role of canonical Wnt signalling in melanoma. Some reports
have shown that canonical Wnt signalling is reduced as melanoma progresses, suggesting that
activating canonical Wnt signalling could be a therapeutic strategy for treatment of melanoma.
Indeed, overexpression of Wnt3a reduced proliferation of human or mouse melanoma cells [204],
and pharmacological activation of Wnt via treatment with Riluzole [205] or a GSK3 inhibitor
(LY2090314) inhibits melanoma cell growth [206]. Conversely, it has been shown that cell intrinsic
canonical Wnt signalling mediates resistance to recent immunotherapy approaches such as PD-1
inhibitors [207], thus suggesting that activation of Wnt would not be an effective therapy, at least not
in combination with the promising immune check point inhibitors. Of note, Wnt5a is able to promote
melanoma progression via Fzd5 and the Ca2+ pathway [132], and as canonical Wnt signalling has
been shown to be able to inhibit non-canonical signalling, this is a potential mechanism that may help
explain how increased canonical Wnt signalling results in reduced melanoma growth [208,209].
FZD7 is upregulated in human, metastatic melanoma cells, and shRNA mediated knockdown of
FZD7 in these cells was able to inhibit formation of xenograft tumours and also metastasis following
intravenous injection [210]. Melanoma’s which develop resistance to treatment with BRAF inhibitor
PLX4720 display upregulated Wnt5a which was consequently show to promote tumour growth
via FZD7 and AKT [208]. Interestingly, treatment of MA-2 human melanoma cells with WNT3 or
LiCl increased canonical WNT signalling, and decreased JNK (non-canonical Wnt signalling) in cells
with FZD7 knockdown, suggesting that FZD7 suppresses the canonical Wnt pathway in melanoma
cells [132].
14. Wilm’s Tumour and Renal Cancer
Wilm’s tumour (WT) is a renal solid tumour, most commonly observed in children. Canonical Wnt
signalling is frequently deregulated in Wilm’s tumour, associated with mutations to β-catenin [211],
and FZD7 is also frequently overexpressed [212].
Inhibition of FZD7 using a blocking antibody resulted in reduced clonality of cancer cells isolated
from human WT samples, and apoptosis in those cells which expressed FZD7. Interestingly, WT cells
become resistant to treatment with FZD7 antibody when SFRP1 or DKK1 are expressed, suggesting
that the Wnt pathway is deregulated at the level of the Wnt receptor complex in WT [213].
In renal cell carcinoma (RCC), Wnt signalling is also activated, with reports of loss of Apc [214]
and mutations to β-catenin [215]. Indeed, conditional truncation of Apc in the kidneys of mice resulted
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in multiple renal tumours, indicating that deregulated canonical Wnt signalling is sufficient to induce
tumourigenesis in the adult kidney [216].
Deregulation of Wnt signalling at the level of the Wnt receptor is also implanted in RCC as
SFRP1, SFRP2, SFRP4, SFRP5, DKK3, and WIF1 are hypermethylated in primary RCC samples [217].
FZD7 has recently been shown to be upregulated in ~36% of human RCC [218]. Addition of Wnt3a
is also sufficient to increase the growth of human RCC cells in vitro, whilst inhibition of FZD7 with
shRNA is able to reduce proliferation in the human RCC cells [218], suggesting FZD7 may be an
attractive therapeutic target to treat RCC. However, the modest reduction in proliferation of RCC
cells upon FZD7 inhibition suggests that strategies combining current standard-of-care therapies for
RCC with FZD7 inhibition could be an attractive approach rather than mono-therapies which are
often unsuccessful.
15. Fzd7 in Other Cancers and Tissues
Deregulated Wnt signalling is observed in many cancers, and, as described above, the Wnt
receptor complex is often involved in this aberrant Wnt activation. Although the role of FZD7 has
not been described in all cancers with high Wnt activity it is tempting to speculate that FZD7 may be
involved in these cancers also, particularly as it is a Wnt target gene [87,88], and it will be interesting
in future studies to examine to full extent to which FZD7 is required in the following cancers.
FZD7 is upregulated in esophageal cancer [95], but there is no functional data to determine
its role. Likewise, FZD7 is upregulated in nasopharyngeal carcinoma [219,220], and Wnt signalling
is deregulated in head and neck cancer [221], but the importance of FZD7 has not been studied.
Wnt signalling is also deregulated in lung cancer [222,223] and prostate cancer [224,225], but it is
unknown if FZD7 is important in these two devastating cancers with very high morbidity rates.
Developmental pathways are often deregulated in cancers, and thus it is tempting to speculate whether
FZD7 may be involved in hematopoietic malignancies as T-cell maturation in the thymus is blocked
by expression of the FZD7 ectodomain [226]. FZD7 is upregulated in human glioblastoma stem cells,
and whilst no experiments have yet been performed to specifically address the role of FZD7 in these
cells, overexpression of sFRP1 halts cell cycle and induces apoptosis, suggesting the Wnt receptor
complex, and possibly FZD7, are attractive targets to treat glioblastoma [227,228].
Wnt signalling does not act alone in promoting cancer, and is able to co-operate with other
pathways, oncogenes and tumour suppressors, including JAK/STAT [229], K-ras [225,230], p53 [216],
mTOR [231] and Notch [232]. Future studies to determine the efficacy of combined targeting of these
factors (or re-expression in the case of p53) along with FZD7 inhibition will yield important pre-clinical
information, which is likely the future of cancer therapy given the failure of mono-therapies to provide
a robust clinical outcome.
16. Targeting FZD7 for the Treatment of Cancer
The plethora of studies detailed above has established that signalling via Wnt/FZD is
epigenetically regulated in many cancers, and therefore offers an attractive target for therapeutic
intervention. As FZD receptors belong to a large family of proteins with high levels of promiscuity
to several Wnt ligands it was initially thought that targeting a single FZD receptor would not be an
effective strategy to treat cancer due to functional redundancy by another FZD receptor. However,
this has not proven to be the case, as experiments inhibiting FZD7 alone have shown that it can have
potent anti-tumour effects, as detailed above. Interestingly, DNA damage induced regeneration in the
intestine was impaired when Fzd7 was deleted, but eventually recovered and was associated with
an increase in the expression of Fzd2, suggesting Fzd2 may have been able to compensate for Fzd7
loss in this setting [62]. It will be interesting in future research to investigate if inhibiting multiple Fzd
receptors is able to increase the anti-tumour effects of targeting Fzd7 by eliminating the redundancy
between receptors.
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Deregulated Wnt signalling in cancer is often the result of mutations to cytoplasmic components
of the Wnt pathway. Although the concept of targeting a receptor for a cancer driven by a mutation to
a downstream, cytoplasm signal transducer (such as Apc), seems counter-intuitive, the Goldilocks
model of Wnt signalling helps explain how this is possible. The data that has contributed to this
model demonstrates that mutations to Apc do not completely prevent its action to regulate β-catenin
and thus upstream events at the level of the receptor can also be targeted in cancers with mutant
Apc [74]. Apc is mutated at several different places, with different levels of Wnt pathway activity
associated with each mutation, most likely as a result of the mutations ability to prevent Apc regulating
β-catenin phosphorylation. Thus, all Apc mutations do not result in the same impact on Wnt signalling,
and it will be useful in future research to map which Apc mutations correlate to a cellular response to
upstream regulators at the level of the ligand/receptor. This information will be important to help
stratify which patients will respond to cancer treatments targeting FZD7 or any other regulators of the
ligand/receptor complex, based on which mutations to Apc their individual cancers have.
Stem cells are required for the continuous tissue maintenance within diverse organs, and Wnt
signalling has been identified as regulating stem cells in several organs including the gastrointestinal
tract, breast, skin, kidney, and ovary [8]. Stem cells are able to self-renew and proliferate autonomously,
if they are located in their niche environment within a tissue, and thus already possess some
characteristics of cancer cells [233]. Consequently, stem cells have been identified as the cells of
origin for several different cancers including the intestine, stomach, prostate and lung [234]. Wnt
signalling has been shown to regulate stem cells in several organs and as such, deregulated Wnt
signalling in stem cells is able to induce tumourigenesis in the intestine and stomach [148]. Fzd7
has recently been demonstrated to be the predominant receptor transmitting critical Wnt signals to
Lgr5+ intestinal stem cells [62]. Although deletion of Fzd7 was deleterious to intestinal stem cells,
the intestine has a remarkable capacity to repopulate the epithelium with non-recombined, Fzd7
proficient cells, and therefore inhibition of Fzd7 is well tolerated. Thus, future tumour prevention
strategies could employ inhibition of FZD7 to prevent Wnt induced transformation of stem cells in FAP
patients who are inherently predisposed to develop this type of pathology due to loss of heterozygosity
of APC. Cancer stem cells are biologically distinct from the differentiated cancer cells that form the
bulk of a tumour, and are often the cells responsible for the continued proliferation and resistance
to therapies of the tumour [235]. Lgr5 also marks cancer stem cells as well as normal stem cells in
intestinal tumours, suggesting FZD7 may offer a novel target to specifically kill cancer stem cells in
established tumours. Notably, FZD7, but not FZD2 or FZD1, expression is dramatically up-regulated
in CRC [158], thus compensation by closely related FZD’s is unlikely. Recently, FZD7+ cells isolated
from Wilm’s tumour were shown to be highly clonogenic and proliferative, displaying many stem like
gene expression patterns and characteristics, and thus inhibition of FZD7 may also be an attractive
strategy to specifically target the cancer stem cells in Wilm’s tumour [213].
Another potential strategy for the use of FZD7 inhibition could be to target disseminated
metastatic cells that are responsible for the development of secondary tumours, often many years after
the primary tumour has been successfully removed by surgery/chemotherapy. Dormant, disseminated
tumour cells are the hindrance to curative treatment for colon cancer, the vast majority of deaths from
colon cancer attributable to tumour recurrence. CRC can metastasise early, long before diagnosis, and
the disseminated cells can sit dormant for many years, providing ample opportunity to target these
cells and eliminate them [152]. As detailed above, FZD7 is able to orchestrate MET in colon cancer
cells which is required for disseminated mesenchymal tumour cells to re-establish a tumour at the
secondary site, therefore, inhibition of FZD7 could prevent these cells from forming metastases at the
new site.
As FZD7 is located on the cell surface, this enables it to be targeted efficiently using antibodies.
Indeed, monoclonal antibodies to target FZD7 developed by Oncomed Pharmaceuticals (OMP-18R5
or Vantictumab) are already in phase 1b clinical trials for solid tumours including colorectal,
neuroendocrine, breast, sarcoma, pancreatic and NSCLC [236]. As Wnt signalling is critical for
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the homeostasis of adult tissues, targeting the Wnt pathway for the treatment of cancer has been
proved very challenging due to toxicity, mainly to the GI tract and bones [237]. Indeed, the initial
enthusiasm for results using Vantictumab were diminished when clinical trials were transiently halted
due to bone related side-effects in ~13% of patients. However, a review of the program and subsequent
revised safety plan has allowed the trial to continue with a more stringent exclusion plan and bone turn
over successfully managed through careful monitoring, and administration of prophylactic Vitamin
D, calcium carbonate and zoledronic acid (clinicaltrials.gov NCT02005315). Although Vantictumab
was identified in a screen for antibodies that bind to FZD7, it also binds with high affinity to several
other FZD receptors including FZD1, 2, 5 and 8 [236]. This may provide for a more potent anti-tumour
effect as it negates the redundancy between FZD receptors but may also facilitate toxicity. Future
therapies targeting a single FZD are an obvious solution to this but the high levels of sequence similarity,
particularly in the N-terminal portion, which would be targeted extracellularly, make this a challenging
prospect. To date there are no antibodies which block a specific frizzled receptor. However, genetic
evidence demonstrates that deletion of Fzd7 is able to significantly reduce the transcription of Wnt
target genes suggesting that such an antibody would be effective in combating specific cancers [62].
Over recent years it has become clear that activation of the Wnt pathway at the level of the
receptor, via upregulation of Wnt ligands and downregulation of Wnt receptor antagonists, plays
a major role in promoting cancer initiation, growth and metastasis. Even cancers which contain
mutations to cytoplamsic transduction components such as APC can respond to FZD7 inhibition.
The mechanism for this is not yet fully understood, but could be dependent on the type of mutation
present in Apc, or the ability of FZD7 to transmit signalling via all the currently known Wnt pathways
and consequently by-pass Apc. Thus, FZD7 acts as the lynchpin for multiple Wnt transduction
pathways, depending on the availability of co-receptors, ligands and antagonists. This promiscuity
of FZD7, may represent the Achilles’ heel of targeting the Wnt receptor complex for the treatment of
cancer, as FZD7 is involved in multiple malignancies characterised by deregulated Wnt signalling.
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Abbreviations
The following abbreviations are used in this manuscript:
Fzd Frizzled
CRD Cysteine rich domain
PDZ amalgam of Post-synaptic density protein 95, Disc-large tumour suppressor andZonula occludens
MMTV Mouse Mammary tumour virus
Wg Wingless
GSK3 Glycogen synthase kinase-3
TCF4 T-cell factor-4
LEF1 Lymphoid enhancer binding factor-1
Apc Adenomatous polyposis coli
CK1 Casein kinase 1
Lrp5/6 Low-density lipoprotein receptor-related protein 5 or 6
Dvl Dishevelled
PCP Planar Cell Polarity
ROR2 Receptor tyrosine kinase-like orphan receptor 2
Ryk Receptor-like tyrosine kinase
JNK c-JUN N-terminal Kinase
PKC Protein kinase C
CaM kinase Calcium/calmodulin-dependent protein kinase
Cancers 2016, 8, 50 21 of 33
RhoA Ras homolog family member A
Rac1 Ras-related C3 botulinum toxin substrate 1
Celsr Cadherin,EGF LAG seven-pass G-type receptor
Vangl Vang-like (“Van Gogh”)
IP3 Inositol 1,4,5-triphosphate
Dag 1,2 diacylglycerol
PLC Phospholipase C
CaMKII Calcium calmodulin dependent protein kinase II (CaMKII)
NFκB Nuclear factor kappa-light-chain-enhancer of B cells
CREB cAMP response element-binding protein
sFRP Secreted Frizzled Related Proteins
Dkk Dickkopf
NTR Netrin realted motif
R-Spo R-Spondin
Lgr4/5 Leucine-rich repeat-containing G-protein coupled receptor 4 or 5
ZNRF3 Zinc-ring finger 3
RNF43 Ring finger 43
Sdc4 Syndecan-4
PKN1 Protein kinase N1
WIF1 Wnt inhibitory factor 1
MAPK Mitogen activated protein kinase
hESCs Human embryonic stem cells
FAP Familial Adenomatous Polyposis
CRC Colorectal Cancer
EMT Epithelial-Mesenchymal transition
MET Mesenchymal-Epithelial transition
HCC Hepatocellular Carcinoma
HBV Hepatitis B Virus
GC Gastric cancer
WT Wilms Tumour
RCC Renal Cell Carcinoma
mTOR Mammalian target of Rapamycin
JAK Janus kinase
STAT Signal Transducer and Activator of Transcription
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